Clinical Trial Update: Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity [Phase 2]

View source ↗

Summary

A Phase 2 pilot study of GFT505 (80 mg) in patients with insulin resistance and abdominal obesity has completed. The sponsor is Genfit.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominal Obesity
• Insulin Resistance

Drugs mentioned

• GFT505

Snippet

Sponsor: Genfit | Conditions: Insulin Resistance, Abdominal Obesity | Phase 2 | Status: COMPLETED